Physician profile
Daniel Gay
NPI 1679716591
$10,771.17
in general payments reported to CMS, 2019-2025
14 companies · $465 in 2025
The $465 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,195 · 2020: $140 · 2021: $267 · 2022: $61.65 · 2023: $57.10 · 2024: $586 · 2025: $465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,107.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $8,142.67 | 2019-2024 | |
| Davol INC. | $1,652.81 | 2019-2025 | Phasix Mesh |
| Tela Bio, INC. | $208.31 | 2022-2025 | Ovitex 2s, Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| C. R. Bard, INC. & Subsidiaries | $207.46 | 2019 | |
| Medtronic, INC. | $153.02 | 2024 | Signia |
| Baxter Healthcare | $146.22 | 2024-2025 | Tisseel, Perclot |
| Boston Scientific Corporation | $92.76 | 2025 | Lumenis Pulse 120h, Spaceoar Vue System - 10ml |
| Smith+Nephew, INC. | $54.92 | 2024 | Pico 7, Renasys Go V2 Home |
| Aroa Biosurgery Incorporated | $27.29 | 2025 | |
| Reprise Biomedical, INC. | $25.64 | 2025 | Miro3d |
| Axonics, INC. | $16.32 | 2024 | Axonics |
| Ethicon US, LLC | $15.24 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $15.16 | 2025 | |
| Kci USA, INC. | $13.35 | 2023 | Snap, V.A.C. Veraflo, V.A.C. Dermatac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Gay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.